Today: 9 June 2026
Joby Aviation stock: Jan. 15 Ohio factory deadline and CPI could shake JOBY next week
11 January 2026
2 mins read

Joby Aviation stock: Jan. 15 Ohio factory deadline and CPI could shake JOBY next week

NEW YORK, Jan 11, 2026, 05:01 EST — Market closed.

Joby Aviation shares enter Monday facing a Jan. 15 deadline to finalize its $61.5 million Ohio factory purchase, following a roughly 0.9% gain on Friday that pushed the stock to $15.39. U.S. markets remain closed over the weekend.

The electric air-taxi maker has moved like a high-beta growth stock, swinging sharply with shifts in market risk appetite. The S&P 500 gained 0.6% on Friday, hitting a new record, while the Nasdaq advanced 0.8%, according to the Associated Press.

The stakes are high for Joby since its commercial passenger launch hinges on Federal Aviation Administration approvals and significant upfront costs, making the stock vulnerable to interest rate moves. S&P Global highlighted Tuesday’s consumer price index (CPI) report as the week’s marquee U.S. data, alongside retail sales and producer prices.

On Jan. 7, Joby’s subsidiary filed with the SEC revealing plans to purchase a 728,000-square-foot property at 1669 Capstone Way in Vandalia, Ohio, for $61.5 million. The deal includes a $1 million escrow deposit and gives Joby until Jan. 15 to back out over any title issues. The purchase must close by Feb. 27.

Joby said the new facility is ready to go and will back its goal to double output to four electric vertical takeoff and landing aircraft — eVTOLs, battery-powered vehicles that lift vertically like helicopters — each month by 2027. Founder and CEO JoeBen Bevirt said, “This site will not only support our near-term plan to double production, it can also serve as a base for significant future growth.” Joby Aviation

Earlier this week, Joby announced it received the first of two CAE flight simulators, with plans for the second—a full-motion model—to arrive before year-end. Together, these simulators are expected to train as many as 250 pilots annually. “These simulators are central to the FAA certification process and are being delivered on time,” said Bonny Simi, Joby’s president of operations. She noted that FAA-approved simulators are mandatory for Part 135 operations, which govern on-demand air-carrier services. Joby Aviation, Inc.

The stock has been volatile since the updates. It soared 11.7% on Jan. 5, only to drop 4.6% two days later on Jan. 7, before settling down toward the end of the week, according to Investing.com data.

Peers moved as well. On Thursday, Archer Aviation announced plans to leverage Nvidia’s IGX Thor platform to build next-gen aviation AI capabilities. This underscores the race among air-taxi developers to secure tech partnerships on the road to certification.

The Ohio purchase isn’t finalized. According to the contract, the $1 million deposit is refundable only under specific conditions and could be forfeited if the deal falls through for other reasons. It also hinges on an investigation period and financing terms.

Joby’s investor relations calendar shows no scheduled events, pushing traders to rely on filings, partner updates, and broader economic data for signals.

The next catalyst hits before Tuesday’s open, with the Bureau of Labor Statistics set to drop December 2025’s CPI at 8:30 a.m. Eastern—a report known to shake up rate-sensitive stocks. For Joby, keep an eye on the Jan. 15 title-objection deadline in the Ohio deal.

Stock Market Today

  • NOV Stock Up 32% in Six Months: Key Factors and Investor Outlook
    June 9, 2026, 10:21 AM EDT. NOV Inc. shares have surged 31.5% over six months, outpacing the Mechanical and Equipment Oil and Gas sub-industry and broader energy sector. The company benefits from strong offshore equipment demand, driven by subsea flexible pipe growth and offshore projects through 2028. NOV's focus on automation and cost reduction, including headcount and facility cuts, supports operational efficiency. Management anticipates a multi-year upcycle in capital equipment spending due to energy security and renewed offshore investment, bolstering demand. With a solid backlog and positive 2026 earnings outlook, NOV's positioning suggests potential for continued gains, raising questions for investors on whether to hold or sell amid market shifts.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut
Previous Story

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms
Next Story

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms

Go toTop